MedTrace Logo

Microbiome Immunotherapy Toxicity and Response Evaluation

NCT04107168 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2023-02-16

No results posted yet for this study

Summary

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.

Conditions

Interventions

DRUG

Nivolumab

A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

DRUG

Pembrolizumab

A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

DRUG

Ipilimumab

A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).

DRUG

Durvalumab

A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).

DRUG

Tremelimumab

A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

DRUG

Atezolizumab

A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).

DRUG

Bevacizumab

A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).

Sponsors & Collaborators

  • Microbiotica Ltd

    collaborator INDUSTRY

  • CCTU- Cancer Theme

    lead OTHER

Principal Investigators

  • Pippa Corrie · Cambridge University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2024-07-08
Completion
2025-07-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04107168 on ClinicalTrials.gov